Wave Life Sciences Ltd.
Wave Life Sciences Announces Positive Phase 1b/2a Trial Results for Huntington's Disease Candidate
Summary
On June 25, 2024, Wave Life Sciences Ltd. announced positive results from its Phase 1b/2a SELECT-HD clinical trial of WVE-003, its candidate for Huntington's disease, evidencing the first clinical demonstration of allele-selective mutant huntingtin (mHTT) lowering. The trial showed a 46% mean reduction in CSF mHTT protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and a safe and well-tolerated profile. Additionally, the reduction in mHTT was correlated with slowing of caudate atrophy, an imaging biomarker predictive of clinical outcomes. Wave plans to engage regulators on a clinical development path for WVE-003 that would support a potential accelerated approval.
Get alerts for WVE
Be first to know when Wave Life Sciences Ltd. files with the SEC.
Filing Categories
Exhibits (1)
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd. is a biotechnology company engaged in the research and development of stereopure nucleic acid therapies. The primary focus of Wave Life Sciences is to leverage its unique platform to design and optimize therapies that modulate RNA to address genetic diseases. This involves developing treatments with high specificity and efficacy, potentially offering advantages over traditional nucleic acid therapies. The company targets a range of serious diseases, including those related to the central nervous system, with its innovative therapies. Wave Life Sciences plays a significant role in the biopharmaceutical industry by expanding the potential of gene medicine. Its work has implications for sectors such as healthcare and pharmaceuticals, especially in developing new treatment modalities for unmet medical needs. The company's research and development efforts are geared towards delivering transformational outcomes for patients, positioning it as a pioneer in the evolving field of genetic medicine. Wave Life Sciences Ltd. claims a critical space within the market for its advancements in precision medicine and continues to collaborate with various stakeholders to push the boundaries of therapeutic development.
Official SEC Documents